Dr. Gelane Gemechisa
And When You Need an Elimination Diet Instead
A patient handed me a lab report last year with forty-three foods marked “reactive.” Egg, garlic, oat milk, and black pepper all scored in the same red band as foods she’d never once eaten, and the report never explained what it had actually measured. It just gave her a list, and with it, a sense that her plate was smaller than she’d thought.
“Food sensitivity” gets used as one phrase for five biologically distinct events: an IgE-mediated allergic response, an IgG antibody signature that mostly reflects exposure, a white blood cell mediator release, a compromised gut barrier letting more through than it should, and a histamine-metabolizing enzyme running low. Each has its own test, and its own gap between what that test measures and what the patient actually wants to know. None of them substitute for watching what a food does to a person’s real symptoms.
What the tests measure
IgE is the only antibody class with a direct link to classic allergy: hives, throat swelling, anaphylaxis. Skin prick tests and serum IgE assays (ImmunoCAP) detect it reliably, but the reference standard for confirming a true allergy remains the oral food challenge rather than the blood draw, and an undetectable IgE result isn’t automatically a negative one. When someone’s reaction is immediate and severe, this is the branch of testing that matters, and the one where a positive result carries real diagnostic weight.
IgG and ELISA panels sit in murkier territory. They measure circulating antibodies to food proteins, and what they mostly capture is exposure rather than reactivity: someone who drinks oat milk daily will show IgG to oats whether or not oats are causing anything. The EAACI Task Force concluded that testing for food-specific IgG4 shouldn’t be used as a diagnostic tool, a position the AAAAI formally endorsed and the CSACI later reiterated, on the grounds that the antibody indicates tolerance more than intolerance.
The clinical picture isn’t quite that tidy, though. A randomized trial published in Gut found IBS patients following an IgG-guided elimination diet did better than those on a sham diet, while a migraine crossover trial found only a modest benefit that faded by twelve weeks. Read together, this is a test with weak mechanistic grounding but occasional positive trial signal in symptom-based conditions, not one that identifies a fixed, discoverable set of “bad foods” for a given person.
MRT, the Mediator Release Test behind the LEAP protocol, works differently again. It measures ex vivo change in blood cell volume after exposure to a food antigen, a proxy for mediator release like cytokines, histamine, and prostaglandins rather than antibody presence, and it doesn’t claim to be an allergy test. A small case series in diarrhea-predominant IBS and a more recent cohort study both showed meaningful symptom reduction following an MRT-guided elimination diet, though the published evidence is still mostly small and uncontrolled, and much of it comes from groups with a commercial stake in the test rather than independent RCTs.
Zonulin and other gut permeability markers measure the door rather than what’s coming through it. Zonulin modulates intestinal tight junctions, and elevated levels have been tied to celiac disease, type 1 diabetes, and other autoimmune conditions in Alessio Fasano’s research program, so it’s a real, mechanistically grounded marker of barrier function. But it tells you nothing about which specific food, if any, is driving that permeability for a given patient, and the commercially available zonulin panels haven’t been validated to the standard the underlying science deserves.
Histamine intolerance is the category most often left off these comparisons, mostly because it isn’t an immune reaction at all. Diamine oxidase breaks down dietary histamine in the gut lining, and when that enzyme runs low, histamine accumulates and produces a grab bag of symptoms (flushing, headache, hives, GI upset) that overlaps heavily with what people call food sensitivity. There’s no validated biomarker for this condition, so diagnosis rests on clinical pattern and response to a low-histamine diet with reintroduction, the same elimination logic as everything else here, just aimed at a different mechanism. Serum DAO tests exist, but they don’t reliably predict who responds to the diet.
What elimination actually measures
Testing infers. Elimination-reintroduction observes. It’s an n-of-1 trial: remove foods, watch what happens, add them back one at a time, and let the person’s own physiology answer a question a blood panel can only estimate.
The broadest version is standard oligoantigenic elimination, built on a short list of foods unlikely to provoke a reaction (lamb, pear, rice, and similar), with everything else added back systematically over two to six weeks. This is the design behind two of the older, still-cited trials in the field, a Lancet study linking food intolerance to IBS symptom generation and a separate double-blind trial showing oligoantigenic diets reduced migraine frequency in children. It’s a reasonable first move when there’s no clear pattern yet to narrow the search, and it costs nothing but time.
Low-FODMAP runs on a different mechanism entirely. FODMAPs are fermentable short-chain carbohydrates, not immune triggers, and the diet targets IBS and SIBO/IMO-type symptoms rather than antibody-driven reactivity. The Halmos 2014 randomized crossover trial found roughly seventy percent of IBS patients felt meaningfully better within a week on the diet. It gets confused with AIP or general “food sensitivity” elimination fairly often, but it’s solving a fermentation problem rather than an immune one, and it needs a structured reintroduction phase just as much as AIP does, or people end up staying unnecessarily restricted for years.
AIP, the Autoimmune Protocol, is the most restrictive of the group and the one that actually needs an autoimmune diagnosis to justify the trade-off. It targets gluten, lectins, nightshades, and other foods with plausible mechanistic links to gut permeability and immune activation in autoimmune disease specifically, and a small trial in Crohn’s and ulcerative colitis found meaningful clinical and endoscopic improvement over an eleven-week elimination-maintenance protocol.
Then there’s targeted elimination built off a test result, which is where testing actually earns its keep, not as a diagnosis but as triage. A patient facing nine food groups and low tolerance for open-ended elimination does better with a shorter, prioritized list. If an MRT panel flags eight foods strongly, narrowing the initial elimination to those plus a standard core, then still running a real reintroduction against symptoms, is a legitimate use of the test. The test picks the shortlist; the elimination-reintroduction confirms it.
Why the panels keep getting sold
None of this evidence gap is a secret. IgG testing has had a formal “don’t use this for diagnosis” statement from major allergy bodies since 2008, and it’s more available now than it was then, largely because of what each option costs a patient in time and certainty. A lab panel is a single visit and a number. An elimination-reintroduction is weeks of tracking your own symptoms with little external validation along the way, even though it usually arrives at the same clarity the panel promised, just later and with more effort on the patient’s part. For someone already anxious about their body, a number on a page reads as relief in a way that “wait three weeks and see” doesn’t, even when the number means less than it looks like it does.
Which test or diet, for what
An immediate, severe reaction, hives, swelling, trouble breathing, calls for IgE testing and an allergist, not an elimination diet. A diagnosed autoimmune condition with active symptoms and suspected gut-immune crosstalk points toward AIP. IBS-type symptoms with bloating and a suspected fermentation pattern do better starting with low-FODMAP. Flushing, headache, or hives that track with high-histamine foods like aged cheese, wine, or cured meats are worth a low-histamine trial before reaching for a serum DAO panel. And vague, hard-to-place symptoms with no autoimmune diagnosis and no clear GI mechanism are the case for standard oligoantigenic elimination, or a targeted list off MRT if the person needs a shorter starting point to stay adherent.
A lab report with forty-three foods circled in red and no plan for what happens next isn’t a diagnosis. It’s a reason to run the actual experiment.
At Eterna Integrative, that’s usually where we start: not with another panel, but with sorting out which mechanism actually fits the symptoms in front of us, and whether a test has anything real to add before we order one. Sometimes it does. Often the more useful next step is simpler than a lab requisition, just a structured elimination, run properly, with an actual reintroduction plan instead of a list of foods to fear indefinitely.